Autoimmune thrombocytopenia (ITP) following autologous transplantation in solid tumors is a rare phenomenon and only few cases have been reported in literature. 1, 2 Autoimmune thrombocytopenia after double dose-intensive chemotherapy with autologous peripheral blood stem cell transplantation (tandem transplantation) 3 has never been reported. We report the first case of autoimmune thrombocytopenia after tandem transplantation in a patient with a refractory germ cell tumor.
A 45-year-old man with no significant past medical history was diagnosed with stage IIC extra testicular nonseminomatous germ cell tumor (normal tumor markers). After four cycles of bleomycin, etoposide and cisplatin (BEP), persistent retroperitoneal lymphadenopathy was found on CT scan. Bilateral retroperitoneal lymph node dissection revealed viable tumor. He then received two cycles of salvage chemotherapy consisting of vinblastine, ifosfamide and cisplatin (VeIP). Shortly thereafter, he developed recurrent retroperitoneal lymphadenopathy with elevation of tumor markers, a-fetoprotein 1050 mg/l and b-hcg 16 U/l (normal values: a-fetoproteino9 mg/l and b-hcgo6 U/l). He was then considered to be an appropriate candidate for tandem autologous transplantation. Highdose cytoxan and etoposide with granulocyte colonystimulating factor (G-CSF) was used for peripheral blood stem cell (PBSC) mobilization and 18 Â 10 6 CD 34 þ cells/ kg of body weight were obtained. He underwent the first autologous PBSC transplant with carboplatin 250 mg/ m 2 Â 3 days, etoposide 1200 mg/m 2 Â 2 days and cytoxan 1800 mg/m 2 Â 5 days along with mesna, and received 9 Â 10 6 CD34 þ cells/kg of body weight. Blood counts recovered by day 12 (neutrophils 41 Â 10 9 /l, hemoglobin 480 gm/l without transfusion and platelets 450 Â 10 9 /l without transfusion). Tumor markers normalized. He then underwent the second autologous PBSC transplant 8 weeks after first transplant with the same regimen and received the same dose of CD34 þ cells. Counts recovered by day 12. He received G-CSF from day 1 after both transplants. A sudden drop in the platelet count to 7 Â 10 9 /l was noted on day þ 70 after the second transplant. White cell count, hemoglobin and blood coagulation parameters were normal. The peripheral smear did not reveal any abnormality except for thrombocytopenia. After the platelet transfusion, no significant post-transfusion increments were observed. His medications were reviewed and hepatitis A, B, C, CMV and HIV as potential causes for thrombocytopenia were excluded. A bone marrow examination performed on day þ 71 after the second transplant showed megakaryocytic hyperplasia, suggesting peripheral destruction of platelets rather than decreased production. He did not respond adequately to steroid and i.v. IgG and underwent splenectomy. After a transient improvement in the platelet count, the patient had relapse of ITP and was re-started on prednisone. Currently, his ITP is in remission on low doses of prednisone.
Immunologic abnormalities, such as generation of autoreactive antibodies, have been reported after autologous bone marrow or PBSC transplant, 4,5 and can take the form of autoimmune thyroiditis, neurological immune disease or autoimmune cytopenias as well as autoimmune thrombocytopenia. Pathogenesis of autoimmunity in the post-autologous transplant setting is unclear. Alteration in immune reconstitution resulting in immune dysregulation, due to inhibition of thymus-dependent clonal deletion of autoreactive T-lymphocytes, is a likely explanation. 6 Another hypothesis could be that, after intensive chemotherapy and during hematopoietic recovery, platelet micro particles may be produced, carrying altered selfantigens leading to autoimmune thrombocytopenia. 7 Furthermore, it has been reported that some of those patients who had autoimmune thrombocytopenia or other autoimmune events after autologous transplant had experienced long-term disease-free survival despite poor prognostic factors. 8 Our patient with platinum refractory germ cell tumor is also in complete remission, 8 months after transplant. Relatively long-term survival of these patients, despite their limited number, recalls observations of autologous graft-versus-host disease, associated with antitumor activity. 
